Phase IIThyroid Analog
Compound 61723
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061723
Risk Class
MODERATE
Last Audit
Jun 30, 2108
Research Abstract
Thyroid Analog candidate engineered for oncology adjuvant initiatives with automated dossier coverage.
Compound 61723 is a thyroid analog asset inside thyroid analog innovation track initiatives, optimized for oncology adjuvant and inflammation control.
The dossier currently sits in phase ii with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061723 with updates logged 2108-06-30.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Oncology adjuvantInflammation control
Nomenclature
CX-61723Thyroid Analog Program 61723
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061723
- [2] Operations Pulse • Thyroid Analog innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61723